Mar 19 |
Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement
|
Mar 5 |
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
|
Mar 1 |
Fate Therapeutics, Inc. (NASDAQ:FATE) Q4 2023 Earnings Call Transcript
|
Mar 1 |
Fate Therapeutics to Present at Upcoming March Investor Conferences
|
Feb 29 |
Fate Therapeutics, Inc. (NASDAQ:FATE) Just Reported And Analysts Have Been Lifting Their Price Targets
|
Feb 28 |
Fate Therapeutics Full Year 2023 Earnings: EPS Beats Expectations
|
Feb 27 |
Fate Therapeutics (FATE) Q4 Earnings Beat, Revenues Fall Y/Y
|
Feb 27 |
Q4 2023 Fate Therapeutics Inc Earnings Call
|
Feb 27 |
Fate Therapeutics, Inc. (FATE) Q4 2023 Earnings Call Transcript
|
Feb 26 |
Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates
|